Bozen, Sud-Tirol, Italy – July 30th, 2012.
Health Robotics today announced that i.v.STATION and Mangiagalli’s Clinic won a national grant from the Vodafone Foundation, as selected by Vodafone customers’ votes from a group of potential projects, all of which were focused on children’s welfare. This grant provided funding for the i.v.STATION Robot at Mangiagalli, where 6,500 children are born every year, many of them requiring intensive care and complex medication dilutions (including multi-ingredient and double dilutions).
Professor Fabio Mosca, Director of the Neonatology and Neonatal Intensive Care Unit at Ospedale Maggiore Policlinico’s Mangiagalli Institute, stated: “I’m very pleased to have finally found in i.v.STATION the right technology to handle the complexity of Sterile Compounding for Neonatal Care. I’m also very proud that this world-class Robot is implemented in such a challenging environment as Mangiagalli, in synergy with all the other advanced technologies at our disposal. After extensive due diligence, I’m sure that i.v.STATION will allow us to close the loop in therapeutics, and offer maximum safety to our life-critical newborns.”
Health Robotics’ i.v.STATION and i.v.STATION ONCO’s small footprint allow their installation in direct patient care areas, while their unique features such as complex drug dilutions in vials, syringes, and I.V. Bags are also behind the success that Health Robotics has experienced with its 2nd Generation Robots in the past 2+ years, dominating the world’s I.V. Automation industry over its competitors1.
Gaspar DeViedma, Health Robotics’ Executive Vice President, stated: “This is yet another testimonial to the fact that Health Robotics is the only I.V. Automation company in the world that currently provides complex medication dilutions and multi-ingredient Sterile Compounding. We warmly welcome Mangiagalli to the growing list of prestigious hospitals implementing i.v.STATION for Pediatric and Neonatal Care, such as Children’s Hospital of Los Angeles, Duke University Children’s Hospital, Miller Children’s Hospital, Sophia Children’s Hospital at Erasmus University Medical Center, and Ankara Numune Hospital.”
About Mangiagalli’s Institute at Ospedale Maggiore Policlinico, Milan:
The Neonatal Intensive and Special Care Units at Mangiagalli aim to offer specialized care and treatment to patients from Milan and the Lombardy region. The Department of Neonatal Medicine has 15 beds in Neonatal Intensive Care,
1 Competitors: Loccioni, IHS/RIVA, MDS (now Fresenius Kabi), FHT/Baxa (now Baxter) and 38 beds in the Special Care Unit. As part of the IRCCS Foundation (Istituto di Ricovero e Cura a Carattere Scientifico), the Ospedale Maggiore Policlinico Mangiagalli and Regina Elena, and the Neonatology and Neonatal Intensive Care Unit are committed to improve the training provided to health professionals and increasing scientific research by including collaborative projects with the University of Milan. For more information, please visit: http://www.mangiagalli.it/
About Health Robotics:
Founded in 2006, Health Robotics is the undisputed global leading supplier of life- critical intravenous medication robots, winning 100% of all worldwide I.V. Robot’s publicly announced purchases in 2010 and 2011, and providing over 300 hospital installations in 5 continents with robotics-based technology and clinical software automation solutions. Health Robotics’ world-leading solutions CytoCare® and i.v.STATION® ONCO [hazardous IVs], i.v.STATION® [non-hazardous IVs], i.v.SOFT® [workflow engine for sterile compounding], OMM® [Oncology Medication Management], MEDarchiver® [life-critical clinical information system], and TPNstation® [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals’ growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics’ products help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances’ diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff.
Download in PDF Format :